Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed

Maintenance therapy with olaparib is potentially a cost-effective option in this setting, but this could be improved by tailoring treatment based on individual patient factors.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news